Roquefort Therapeutics is selling its subsidiary, Lyramid, in a $10.8 million deal with Pleiades Pharma. The deal gives Roquefort a stake in a clinical portfolio led by an experienced team, with shares as payment and some potential upfront cash.
Staying with biopharma, Arecor Therapeutics is pushing ahead with its next-generation ultra-rapid insulin. Talks are underway for a co-development deal, aiming to integrate the therapy into next-gen insulin pumps to improve diabetes management.
EMV Capital portfolio company ProAxsis is raising £800,000 to expand its business and support clinical research. The company says it made solid progress in 2024, strengthening its commercial platform and advancing trials in COPD.
And IQ-AI’s Imaging Biometrics has expanded its distribution deal with Blackford Analysis, part of Bayer. More of its AI-powered imaging tools will now be available to hospitals and healthcare providers worldwide.
In mining news, Ariana Resources says drilling at its Dokwe gold project in Zimbabwe looks promising. One hole found two metres of high-grade gold at 17.11 grams per tonne, extending the strike length to 270 metres.
